Vaccinogen Inc. (VGEN) 2.5000 $VGEN
Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board
PR Newswire - Tue May 05, 6:00AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced that its Board of Directors has unanimously elected Co-founder, President, Chief Executive Officer and current Director, Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Benjamin S. Carson, Sr., MD, who resigned from the Board and his role as Chairman and a member of Vaccinogen's Medical Advisory Board role to pursue his candidacy for the President of the United States via the Republican nomination.
Vaccinogen Elects Ronald Kaiser to Board of Directors
PR Newswire - Tue Feb 17, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Ronald W. Kaiser, a biotech executive leader with more than 35 years of financial and accounting expertise, has been elected to the company's Board of Directors. Mr. Kaiser will also chair the company's Audit Committee and serve on the company's Nominating and Corporate Governance Committees.
Vaccinogen Elects Hakan Edstrom to Board of Directors
PR Newswire - Tue Feb 10, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Hakan Edstrom, a healthcare industry veteran with more than 40 years of experience, has been elected to the company's Board of Directors. He will also chair the company's Compensation Committee in this new role and serve on the company's Audit Committee.
Vaccinogen Closes Second Tranche of $80 Million Financing at $5.50 per Unit
PR Newswire - Wed Jan 28, 7:30AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced the closing of the second $10 million tranche of the $80 million financing announced last August. This 2nd tranche brings the total amount closed to $20 million of the $80 million committed at $5.50 per share or unit.
Vaccinogen Names Dr. Peter Morsing as Head of Business Development
PR Newswire - Mon Jan 12, 8:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leader in cancer immunotherapy development, announced today that Peter Morsing, Ph.D., a 20-year pharmaceutical industry veteran, has joined the company as Head of Business Development.
InsiderInsights.com Daily Round Up 1/9/15: OAS, OPK, RM, VVUS
InsiderInsights - at Seeking Alpha - Sun Jan 11, 12:09AM CST
PATK: 38.95 (+0.90), SVU: 7.98 (+0.15), VVUS: 2.15 (+0.02), BBY: 33.93 (+0.26), CRDS: 1.33 (+0.04), RM: 17.20 (-0.03), BRT: 6.86 (+0.05), WIW: 11.20 (-0.07), UNFI: 63.97 (+1.12), GEVA: 238.60 (+2.80), OPK: 16.55 (-0.01), CUDA: 31.55 (-7.57), NSAM: 18.41 (+0.06), WYY: 1.80 (+0.04), OAS: 12.51 (-0.91), RFP: 10.45 (+0.14), CRM: 71.14 (+1.18), NRF: 15.93 (+0.10)
Vaccinogen Completes Initial Closing of an $80 Million Financing
PR Newswire - Mon Aug 25, 6:00AM CDT
Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. Vaccinogen received gross proceeds of $10 million in this first closing.
Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board
PR Newswire - Tue May 05, 6:00AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced that its Board of Directors has unanimously elected Co-founder, President, Chief Executive Officer and current Director, Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Benjamin S. Carson, Sr., MD, who resigned from the Board and his role as Chairman and a member of Vaccinogen's Medical Advisory Board role to pursue his candidacy for the President of the United States via the Republican nomination.
Vaccinogen Elects Ronald Kaiser to Board of Directors
PR Newswire - Tue Feb 17, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Ronald W. Kaiser, a biotech executive leader with more than 35 years of financial and accounting expertise, has been elected to the company's Board of Directors. Mr. Kaiser will also chair the company's Audit Committee and serve on the company's Nominating and Corporate Governance Committees.
Vaccinogen Elects Hakan Edstrom to Board of Directors
PR Newswire - Tue Feb 10, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Hakan Edstrom, a healthcare industry veteran with more than 40 years of experience, has been elected to the company's Board of Directors. He will also chair the company's Compensation Committee in this new role and serve on the company's Audit Committee.
Vaccinogen Closes Second Tranche of $80 Million Financing at $5.50 per Unit
PR Newswire - Wed Jan 28, 7:30AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced the closing of the second $10 million tranche of the $80 million financing announced last August. This 2nd tranche brings the total amount closed to $20 million of the $80 million committed at $5.50 per share or unit.
Vaccinogen Names Dr. Peter Morsing as Head of Business Development
PR Newswire - Mon Jan 12, 8:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leader in cancer immunotherapy development, announced today that Peter Morsing, Ph.D., a 20-year pharmaceutical industry veteran, has joined the company as Head of Business Development.
InsiderInsights.com Daily Round Up 1/9/15: OAS, OPK, RM, VVUS
InsiderInsights - at Seeking Alpha - Sun Jan 11, 12:09AM CST
PATK: 38.95 (+0.90), SVU: 7.98 (+0.15), VVUS: 2.15 (+0.02), BBY: 33.93 (+0.26), CRDS: 1.33 (+0.04), RM: 17.20 (-0.03), BRT: 6.86 (+0.05), WIW: 11.20 (-0.07), UNFI: 63.97 (+1.12), GEVA: 238.60 (+2.80), OPK: 16.55 (-0.01), CUDA: 31.55 (-7.57), NSAM: 18.41 (+0.06), WYY: 1.80 (+0.04), OAS: 12.51 (-0.91), RFP: 10.45 (+0.14), CRM: 71.14 (+1.18), NRF: 15.93 (+0.10)
Vaccinogen Completes Initial Closing of an $80 Million Financing
PR Newswire - Mon Aug 25, 6:00AM CDT
Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. Vaccinogen received gross proceeds of $10 million in this first closing.
